In Study, Diabetes Drug Mounjaro Helped Dieters Shed an Average of 60 Pounds
MONDAY, Oct. 16, 2023 (HealthDay News) — A new trial demonstrates the power of the diabetes drug Mounjaro in fighting obesity, helping folks who used the medication lose about 60 pounds.”In this study, people who added tirzepatide [Mounjaro] to diet …
Learn MoreDaily Oral PrEP Has Highest Preference Ranking Among Young Men
THURSDAY, Oct. 12, 2023 (HealthDay News) — Daily oral preexposure prophylaxis (PrEP) has the highest preference ranking among young men who have sex with men, according to a study recently published in the Journal of the International AIDS Society.Ka…
Learn MoreFDA Warns of Dangers of Compounded Ketamine for Psychiatric Use
WEDNESDAY, Oct. 11, 2023 (HealthDay News) — The U.S. Food and Drug Administration is warning consumers about risks of using compounded versions of the drug ketamine, often taken for psychiatric disorders. Compounded products are not evaluated by the …
Learn MoreNovel Potassium Channel Opener Safe, Effective for Adults With Focal Epilepsy
WEDNESDAY, Oct. 11, 2023 (HealthDay News) — XEN1101 appears safe and effective for the treatment of focal-onset seizures (FOSs), according to results of a phase 2b study published online Oct. 9 in JAMA Neurology.Jacqueline A. French, M.D., from the N…
Learn MoreWegovy, Ozempic Help Folks Lose Weight, But How?
TUESDAY, Oct. 10, 2023 (HealthDay News) — As many doctors and patients hail the advent of weight-loss drugs like Ozempic and Wegovy as the perfect fix for obesity, some experts are urging caution.The drugs are not well-tolerated by everyone strugglin…
Learn MoreLa escasez de medicamentos contra el cáncer persiste en EE.UU.
VIERNES , 6 de octubre de 2023 (HealthDay News) — Los centros contra el cáncer en EE.UU. continúan enfrentando la escasez de medicamentos de quimioterapia más utilizados, de acuerdo con una nueva encuesta, aunque el problema es menor al registrado e…
Learn MoreGI Adverse Events Increased With Use of GLP-1 Agonists for Weight Loss
FRIDAY, Oct. 6, 2023 (HealthDay News) — Use of glucagon-like peptide 1 (GLP-1) receptor agonists for weight loss is associated with increased risks for pancreatitis, gastroparesis, and bowel obstruction compared with use of bupropion-naltrexone, acco…
Learn MoreReductions Seen in HbA1c, Body Weight With Once-Weekly Tirzepatide
FRIDAY, Oct. 6, 2023 (HealthDay News) — For patients with inadequately controlled type 2 diabetes, once-weekly subcutaneous injections of tirzepatide yield reductions in hemoglobin A1c (HbA1c) and body weight compared with insulin lispro, according t…
Learn MorePsychotropic Medication Use Up in Children, Teens With Type 1 Diabetes
THURSDAY, Oct. 5, 2023 (HealthDay News) — Dispensing of psychotropic medication increased among children and adolescents with type 1 diabetes (T1D) from 2006 to 2019, according to a study published online Oct. 3 in JAMA Network Open.Shengxin Liu, fro…
Learn MoreEsketamine Nasal Spray Beneficial for Treatment-Resistant Depression
THURSDAY, Oct. 5, 2023 (HealthDay News) — For patients with treatment-resistant depression, esketamine nasal spray is superior to extended-release quetiapine with respect to remission at week 8, according to a study published in the Oct. 5 issue of t…
Learn More